Prognostic Effect of Psoas Muscle Index, a Parameter of Sarcopenia, in Solid Cancer Patients Receiving Immunotherapy

Basit Öğe Kaydı
dc.contributor.authorOnder, Arif Hakan
dc.contributor.authorBeypınar, Ismail
dc.contributor.authorSozer, Yildiz Kılar
dc.date.accessioned2026-01-24T12:01:05Z
dc.date.available2026-01-24T12:01:05Z
dc.date.issued2023
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractObjectives: In this study, our objective was to evaluate the prognostic feature of sarcopenia and prognostic labora- tory markers, defined by using PMI measurement in patients with kidney cancer and malignant melanoma, receiving immunotherapy. Methods: Diagnosed with and followed up for kidney cancer (RCC) and malignant melanoma (MM) and received Nivolumab immunotherapy in the Oncology Clinic, were retrospectively analyzed. Laboratory examinations and CT images used for staging in the diagnosis were retrospectively used for psoas muscle measurements. Results: We investigated the effect of pretreatment PMI on survival and response to treatment. For this purpose, 93 patients with malignant melanoma (n=45) and kidney cancer (n=48) were included in the study. Among female pa- tients with and without sarcopenia at baseline, median progression-free survival was 30.2 and 50.1 months (p=0.769), respectively, while in men, conversely, 54.8 and 34.3 months (p=0.307), respectively. Median overall survival was 31.0 and 51.7 months (p=0.763) in female patients with and without sarcopenia, respectively, and 62.9 and 52.4 months in males with and without sarcopenia (p=0.906). Conclusion: This result may suggest that sarcopenia has a negative effect on the immune response. It should be con- sidered that sarcopenia may affect the clinical outcomes of immunotherapy. Further studies are needed.
dc.identifier.doi10.14744/ejmi.2023.30675
dc.identifier.endpage372
dc.identifier.issn2602-3164
dc.identifier.issue4
dc.identifier.startpage361
dc.identifier.trdizinid1266582
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1266582
dc.identifier.urihttps://doi.org/10.14744/ejmi.2023.30675
dc.identifier.urihttps://hdl.handle.net/20.500.12868/3990
dc.identifier.volume7
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofEurasian Journal of Medical Investigation
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_TR-Dizin_20260121
dc.subjectSarcopenia
dc.subjectimmunotherapy
dc.subjectsolid cancer
dc.subjectPMI
dc.subjectmetabolic index
dc.titlePrognostic Effect of Psoas Muscle Index, a Parameter of Sarcopenia, in Solid Cancer Patients Receiving Immunotherapy
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu